Microbial limits reviewed: The basis for unique Australian regulatory requirements for microbial quality of non-sterile pharmaceuticals

PDA Journal of Pharmaceutical Science and Technology

Volumn 52, Issue 3, 1998, Pages 100-109

  Tang, Shelley ^a,b  

^a THERAPEUTIC GOODS ADMINISTRATION   (Australia)

^b PO Box 100 ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; BACTERIUM CONTAMINATION; DRUG CONTAMINATION; DRUG MANUFACTURE; DRUG STERILITY; GOOD MANUFACTURING PRACTICE; REVIEW; STANDARD;

AUSTRALIA; DRUG CONTAMINATION; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS;

EID: 0031814629     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. L. O. Kallings, O. Ringertz, L. Silverstolpe, and F. Ernerfeldt, "Microbiological contamination of medical preparations," Acta Pharm. Suecica 3, 219 (1966).
2. WHO/PHARM/69.453, Microbiological Contamination of Non-sterile Drills, World Health Organisation (1969).
3. Gemeinsamer Bericht des Komitees der Offiziellen Laboratorien und Dienststellen zur Kontrolle von Medikamenten und der Sektion der Industrie-Apotheker FIP, Mikrobiologische Reinheit von Arzneimitteln, die nicht steril sein müssen Prüfmethoden, Pharm Acta Helv, 51, 3, 41-49 (1976).
4. W. R. Frieben and J. M. Price, "Controlling the Microbiological Quality of Nonsterile Pharmaceuticals," Pharmaceutical Manufacturing, 1, 10, 23-26 and 60 (1984).
5. G. Y. Kivman, Y. F. Krylov, K. A. Kagramanova, and T. A. Shub, "Problems and methods of estimation of microbial contamination of non-sterile drugs (review)," Pharm Chem J. 17, 294-302 (1984).
6. J. Dony and P. Gerard, "La contamination microbienne des médicaments et l'établissement de normes de qualité bactériologique," J Mond Pharm, 1, 11, 19-32 (1968).
7. Anon, "Microbial contamination in pharmaceuticals for oral and topical use: Society's working party report," The Pharmaceutical Journal, October 23, 1971, pp 400-402.
8. Australian Pharmaceutical Manufacturers Association Inc, "The Control of Microbial Contamination in Non Sterile Pharmaceutical Products for Human Use," March 1990.
9. Therapeutic Goods Administration GMP Newsletter, 9, 13-15, (August 1990).
10. The United States Pharmacopeial Convention Inc, (1111) Microbiological Attributes of Pharmacopeial Articles, Pharmacopeial Forum, 22, No6, 3098-3102, (1996).
11. P. Gilligan, "Report on the consensus document for microbiology and infectious diseases in cystic fibrosis," Clinical Microbiology Newsletter, 18, No 11, 83-87 (1996).
12. J. R. W. Govan, J. E. Hughes, and P. Vandamme, "Burkholderia cepacia: medical, taxonomic and ecological issues," J Med Microbiol, 45, 395-107 (1996).
13. T. Robin and J. M. Janda, "Pseudo-, Xantho-, Stenotrophomonas maltophilia: An emerging pathogen in search of a genus," Clinical Microbiology Newsletter, 18, No 2 (1996).
14. R. M. Baird and R. A. Shooter, "Pseudomonas aeruginosa infections associated with use of contaminated medicaments," Br. Med. J. 2, 349-350 (1976).
15. W. C. Noble and J. A. Savin, "Steroid cream contaminated with Pseudomonas aeruginosa," Lancet, i, 347-349 (1966).
16. I. Phillips, "Postoperative respiratory tract infection with Pseudomonas aeruginosa due to contaminated ligriocaine jelly. Lancet, i 903-906 (1966).
17. F. R. Reid and T. O. Wood, "Pseudomonas corneal ulcer, The causative role of contaminated eye cosmetics," Arch. Ophthalmol., 97, 1640-1641(1979).
18. P. C. Hardy, G. M. Ederer, and J. M. Matsen, "Contamination of commercially packaged urinary catheter kits with the pseudomonad EO-1," Medical Intelligence 282, Nol (1970).
19. W. Schaffner, G. Reisig, and R. Verrall, "Outbreak of Pseudomonas cepacia infection due to contaminated anaesthetics," Lancet, i, 1050-1051 (1973).
20. D. C. J. Bassett, "Wound infection with Pseudomonas multivorans," Lancet, i, 1180-1191 (1970).
21. L. A. Roberts, P. J. Collignon, V. B. Cramp, S. Alexander, A. E. McFarlane, E. Graham, A. Fuller, V. Sinickas, and A. Hellyar," An Australia-wide epidemic of Pseudomonas pickttii bacteraemia due to contaminated 'slerile' water for injection," The Medical Journal of Australia, 152, 652-655 (1990).
22. The United States Pharmacopeial Convention Inc, "Microbial contami" nation of sterile and non-sterile articles, with special reference to Pseudomonas cepacia," Pharmacopeial Forum, July-Aug 1982, p 2239.
23. S. Tang and D. Phillips, "Assessment of alternative methods for the recovery of Pseudomonas species," NBSL Laboratory Information Bulletin, 1, No 4 (1988).
24. A. Hart, K. E. Moore, and D. Tall, "A comparison of the British Pharmacopoeia (1973) and United States Pharmacopeia (1975) methods for detecting pseudomonads," 41, 235-242 (1976).
25. Food and Drug Administration, "FDA Guide to Inspections of Microbiological Pharmaceutical Quality Control Laboratories," FDA Division of Field Investigations. July 1993.
26. The Gold Sheet, F-D-C Reports, Inc, June 1993, 27, No 6.
27. The Gold Sheet, F-D-C Reports Inc, January 1990, 24, No 1.
28. The Gold Sheet, F-D-C Reports Inc, January 1991, 25, No 1.
29. The Gold Sheet, F-D-C Reports Inc, January 1994, 28, No 1.
30. The Cosmetic, Toiletry and Fragrance Association of Australia, "Code of Good Manufacturing Practice and Technical Notes," June 1986.
31. H. G. Bathgate, H. A. Cameron, A. J. Garrard, and G. Christie, "Antiseptic products-assessment of microbiological quality," TGA Laboratory Information Bulletin, 5, No 1, 1-12 (1993).
32. S. Lewin, P. Nicholas, R. Soldiviero, R. Holtzman, A. Florman, H. Frielich, D. Craven, B. Moody, M. Connolly, K. Stottmeier, W. McCabe, N. Miranda, S. Friedman, L. Budnick, S. Shapiro, L. Lyon, and N. Fiumara, "Contaminated povidone iodine solution," Morbidity and Mortality Weekly Report, 29, 553-555 (1980).
33. J. D. Siegel, P. N. Duer, C. E. Haley, K. A. Thomassen, and D. M. Perrotta, "Contaminated povidone-iodine solution-Texas," Morbidity and Mortality Weekly Report, 38, 133-134 (1989).
34. P. L. Parrott, P. M. Terry, B. Whitworth, L. Frawley, and R. C. Coble, "Pseudomonas aeruginosa peritonitis associated with contaminated poloxamer-iodine solution," The Lancet, i, 683-685 (1982).
35. T. J. Sizer, D. Howells, and G. Parton, "Contaminated alcohol solutions," The Pharmaceutical Journal, 235, 668 (1985).
36. "Alcohol - Six Reasons for More Care," GMP Newsletter, September 1989, TGA Audit and Licensing Section.
37. O. Ringertz and S. Ringertz, "The clinical significance of microbial contamination in pharmaceutical and allied products," Advances in Pharmaceutical Sciences, 5, 201-225 (1982).
38. J. A. Savin, "The microbiology of topical preparations in pharmaceutical practice-clinical aspects," The Pharmaceutical Journal. September 23, 1967, 285-288.
39. P. H. Cox and B. A. Sewell, "The metabolism of steroids by Cladosporium herbarum," J Soc Cosmet Chem, 19, 461-467 (1968).
40. E. F. Drion and D. A. A. Mossel, The reliability of the examination of foods, processed for safety, for enteric pathogens and Enterobacteriaceae: a mathematical and ecological study, J Hyg Camb, 78, 301-324 (1977).
41. C. H. Collins, P. M. Lyne, and J. M. Grange, Collins and Lyne's Microbiological Methods, 7th ed, Butterworth-Heinemann Ltd; London, 1995, p. 303.
42. WHO/PHARM/92.559/rev.1, "Quality Control Methods for Medicinal Plant Materials," Section 16, Determination of Microorganisms, 48-54, 1996.
43. S. Tang, "Microbiological quality of herbal teas," TGA Laboratory Information Bulletin, 6, No I. September 1994.
44. M. V. Martin and C. A. Bartzokas, "The boiling of instruments in general dental practice: a misnomer for sterilisation," Br Dent J, 159, 18-20 (1985).
45. W. G. Murrell "Bacillus cereus" in Buckle KA (ed) Foodborne Microorganisms of Public Health Significance, Fourth Edition, Australian Institute of Food Science and Technology (NSW Branch) Food Microbiology Group, 1989.
46. R. J. Gilbert, "Food Poisoning from Bacillus cereus and other Bacillus species," paper presentation at the 6th Australian Food Microbiology Conference, September 1988.
47. K. Longstaff, V. Christ, S. Tang, K. Rusbridge, K. Eves, M. Palmer, and D. Phillips, "Salmonella in a laxative: an unsettling problem," Poster presentation at the International Meeting and Exhibition of the Australian and New Zealand Societies for Microbiology, Christchurch, New Zealand, September 1996.
48. V. Alonzo, M. T. Monforte, G. Tumino, S. Ragusa, and G. Bisignano, "A note on the microbial contamination of medicinal plants," Pharm-Europa. 6, No. 1, 47-55 (1994).
49. L. Kabelitz,"Microbiological Contamination of Herbal Drugs and Spices," Zeitschrift für Phytotherapie, 17, 2, Supplement: Herbal Drugs and Spices, pp 9-16 (1996).
50. B. McCall, D. Strain, S. Hills, M. Heymer, J. Bates, D. Murphy, R. Kelly, and D. Price, "An outbreak of Escherichia coli 0157 infection on the Gold Coast," Communicable Diseases Intelligence, 20, No 10, 236-239 (1996).
51. M. R. Oliver, W. C. Van Voorbis, M. Boeckh, D. Mattson, and R. A. Bowden, "Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine," Clinical Infectious Diseases, 22,521-524 (1996).
52. J. Pin and A. Hocking, in "Foodborne Microorganisms of Public Health Significance," Fifth Edition, Australian Institute of Food Science and Technology (NSW Branch) Food Microbiology Group, 1997.
53. PA/PH/Exp. 1CM/T (95) 10, ANP, 2.16.12. "Microbiological examination of non-sterile products-total viable count," PharmEuropa, 8, No 2, 214-219 (1996).
54. The United States Pharmacopeial Convention Inc, (1111) Microbiologcal Attributes of Pharmaceutical Raw Ingredients, Excipients, Drug Substances, and Nonsterile Dosage Forms, Pharmacopeial Forum, 18, No 4, 3596-3600.
55. M. Cooper (ed), "Non-sterile Products," The Microbiological Update, 14, No 11, February 1997.
56. European Pharmacopoeia Third Ed, Supplement 1998, 2.6.1. "Sterility"